Aktuellt
SENASTE
Redeye leaves a comment following Lipum’s announcement of positive top-line results from the phase I clinical trial with its lead candidate SOL-116. We are encouraged to learn that the candidate demonstrated a robust safety and tolerability profile, predictable pharmacokinetics and successful suppression of the target protein (BSSL).
LÄS MER
